切换至 "中华医学电子期刊资源库"

中华移植杂志(电子版) ›› 2022, Vol. 16 ›› Issue (05) : 266 -276. doi: 10.3877/cma.j.issn.1674-3903.2022.05.002

专家论坛

心脏移植术后抗体介导排斥反应研究现况与进展
杨守国1,()   
  1. 1. 200032 复旦大学附属中山医院心脏外科 上海市心血管病研究所 上海市器官移植重点实验室
  • 收稿日期:2022-06-23 出版日期:2022-10-25
  • 通信作者: 杨守国

Current status and progress on antibody-mediated rejection in heart transplantation

Shouguo Yang1,()   

  1. 1. Department of Cardiac Surgery, Zhongshan Hospital, Fudan University; the Shanghai Institute of Cardiovascular Diseases; the Key Lab of Shanghai Organ Transplantation, Shanghai 200032, China
  • Received:2022-06-23 Published:2022-10-25
  • Corresponding author: Shouguo Yang
引用本文:

杨守国. 心脏移植术后抗体介导排斥反应研究现况与进展[J/OL]. 中华移植杂志(电子版), 2022, 16(05): 266-276.

Shouguo Yang. Current status and progress on antibody-mediated rejection in heart transplantation[J/OL]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(05): 266-276.

抗体介导排斥反应(AMR)是心脏移植术后重要的并发症,在国内目前尚未得到足够的重视和充分的研究。目前认为AMR是一个自病理到临床的系列演变过程,启动于免疫要素(抗体、补体)的积累、免疫活化最后终结于组织器官损伤。临床上涵盖了循环抗体沉默期、亚临床期及有症状的AMR期。AMR发病机制是免疫球蛋白与补体沉积在移植物微血管内引发的炎性反应,其中补体活化是关键环节;因此,心肌活检标本中免疫检测补体C4d及C3d阳性,结合组织病理学毛细血管损伤是确诊AMR的必要依据;无创性基因Allomap和供体来源细胞游离DNA检测是筛选和监测的有效手段,但不能作为AMR的确诊方法。AMR的治疗可依据临床分级联合采用:皮质类固醇、静脉注射免疫球蛋白、血浆置换或利妥昔单抗这些证实有效的抗免疫损伤措施;而抗CD52单抗、依库珠单抗、光化学疗法等技术的疗效尚待于进一步验证。

Antibody-mediated rejection (AMR) is proved to be a crucial complication in heart transplantation, which has not been well evaluated and studied in China. Nowadays, it is considered that AMR contains a series of evolution process from pathological changes to clinic manifestation, which starts with the accumulation of immune factors (such as antibody, complement), the activation of complement and ends with graft tissues injury. Clinically, AMR was classified as circulating antibody silent stage, sub-clinical stage and symptomatic AMR stage. The mechanism of AMR involved in an inflammatory reaction induced by deposition of immunoglobulins and complements within the microvessels of the grafts, in which the activation of complements played a core role. Therefore, immunological assay of C4d and C3d in endomyocardial biopsy specimens combined with evidence of histopathology capillaries injury were necessary for the diagnosis of AMR. While noninvasive gene detection with Allomap and donor-derived cell-free DNA were effective method serving as screening and monitoring AMR. Recommendations on management of AMR consisted a combination of corticosteroid, intravenous immune globulin, plasmapheresis or rituximab by scale of AMR, which were proven to be effective against immune injury. However, the efficacy of anti-CD52 monoclonal antibody, eculizumab and photochemotherapy remains to be further evaluated.

表1 ISHLT不同时期AMR病理诊断及分级标准[6]
图1 心脏移植术后AMR组织病理学改变[6]注:AMR.抗体介导排斥反应;a.组织病理学可见毛细血管内皮细胞肿胀,血管内巨噬细胞聚集(HE染色); b.免疫过氧化物酶染色可见血管内CD68染色阳性细胞
表2 AMR的免疫组分与意义
图2 毛细血管C4d和C3d免疫荧光染色(FITC×60)[13]
表3 ISHLT 2013版心脏移植AMR诊断依据[2]
表4 ISHLT 2013版推荐的AMR病理分级标准[2]
1
Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation[J]. J Heart Lung Transplant, 201130(3): 252-269.
2
Berry GJ, Burke MM, Andersen C, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation[J]. J Heart Lung Transplant, 201332(12):1147-1162.
3
Michaels PJ, Espejo ML, Kobashigawa J, et.aj. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease[J]. J Heart Lung Transplant, 200322(1):58-69.
4
Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group: the International Society for Heart Transplantation[J]. J Heart Transplant, 19909(6):587-593.
5
Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-mediated rejection of cardiac transplants[J]. J Heart Lung Transplant, 200625(2):153-159.
6
Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection[J]. J Heart Lung Transplant, 200524(11):1710-1720.
7
Crespo-Leiro MG, Veiga-Barreiro A, Doménech N, et al. Humoral heart rejection (severe allograft dysfunction with no signs of cellular rejection or ischemia): incidence, management, and the value of C4d for diagnosis[J]. Am J Transplant, 20055(10):2560-2564.
8
Hammond EH, Yowell RL, Nunoda S, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications[J]. J Heart Transplant, 19898(6):430-443.
9
Loupy A, Cazes A, Guillemain R, et al. Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy[J]. Am J Transplant, 201111(7):1478-1487.
10
Kfoury AG, Hammond ME, Snow GL, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection[J]. J Heart Lung Transplant, 200928(8):781-784.
11
Abrams J, Amir O, Etheridge WB, et al. Histologic findings proving the existence of humoral rejection in a cardiac allograft[J]. Cardiovasc Pathol, 200716(1):38-42.
12
Chantranuwat C, Qiao JH, Kobashigawa J, et al. Immunoperoxidase staining for C4d on paraffin-embedded tissue in cardiac allograft endomyocardial biopsies: comparison to frozen tissue immunofluorescence[J]. Appl Immunohistochem Mol Morphol, 200412(2):166-171.
13
Rodriguez ER, Skojec DV, Tan CD, et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers[J]. Am J Transplant, 20055(11):2778-2785.
14
Kfoury AG, Stehlik J, Renlund DG, et al. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns[J]. J Heart Lung Transplant, 200625(11):1277-1282.
15
Tan CD, Sokos GG, Pidwell DJ, et al. Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection[J]. Am J Transplant, 20099(9):2075-2084.
16
Behr TM, Richter K, Fischer P, et al. Incidence of humoral rejection in heart transplant recipients treated with tacrolimus or cyclosporine A[J]. Transplant Proc, 199830(5):1920-1921.
17
Hammond EH, Hansen JK, Spencer LS, et al. Vascular rejection in cardiac transplantation: histologic, immunopathologic, and ultrastructural features[J]. Cardiovasc Pathol, 19932(1):21-34.
18
Smith JD, Danskine AJ, Rose ML, et al. Specificity of lymphocytotoxic antibodies formed after cardiac transplantation and correlation with rejection episodes[J]. Transplantation, 199253(6):1358-1362.
19
Reed EF, Hong B, Ho E, et al. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease[J]. Transplantation, 199661(4):566-572.
20
Rose ML. Role of MHC and non-MHC alloantibodies in graft rejection[J]. Curr Opin Organ Transplant, 20049(1):16-22.
21
Faulk WP, Rose M, Meroni PL, et al. Antibodies to endothelial cells identify myocardial damage and predict development of coronary artery disease in patients with transplanted hearts[J]. Hum Immunol, 199960(9):826-832.
22
Nath DS, Ilias Basha H, Tiriveedhi V, et al. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy[J]. J Heart Lung Transplant, 201029(11):1277-1285.
23
Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation[J]. Transplantation, 200171(7):886-892.
24
Zhang Q, Cecka JM, Gjertson DW, et al. HLA and MICA: targets of antibody-mediated rejection in heart transplantation[J]. Transplantation, 201191(10):1153-1158.
25
Lones MA, Czer LS, Trento A, et al. Clinical-pathologic features of humoral rejection in cardiac allografts: a study in 81 consecutive patients[J]. J Heart Lung Transplant, 199514(1 pt 1):151-162.
26
Fedrigo M, Gambino A, Tona F, et al. Can C4d immunostaining on endomyocardial biopsies be considered a prognostic biomarker in heart transplant recipients?[J]. Transplantation, 201090(7):791-798.Erratum in: Transplantation, 2011,15,91(1):135.
27
Koch CA, Khalpey ZI, Platt JL. Accommodation: preventing injury in transplantation and disease[J]. J Immunol, 2004172(9):5143-5148.
28
Grauhan O, Knosalla C, Ewert R, et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation[J]. J Heart Lung Transplant, 200120(3):316-321.
29
Wu GW, Kobashigawa JA, Fishbein MC, et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes[J]. J Heart Lung Transplant, 200928(5):417-422.
30
Mousseaux E, Farge D, Guillemain R, et al. Assessing human cardiac allograft rejection using MRI with Gd-DOTA[J]. J Comput Assist Tomogr, 199317(2):237-244.
31
Butler CR, Thompson R, Haykowsky M, et al. Cardiovascular magnetic resonance in the diagnosis of acute heart transplant rejection: a review[J]. J Cardiovasc Magn Reson, 200911(1):7.
32
Sasaguri S, LaRaia PJ, Fabri BM, et al. Early detection of cardiac allograft rejection with proton nuclear magnetic resonance[J]. Circulation, 198572(3 pt 2):II231-II236.
33
Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling[J]. Am J Transplant, 2006, 6(1):150-160.
34
Starling RC, Pham M, Valantine H,et al. Molecular testing in the management of cardiac transplant recipients: initial clinical experience[J]. J Heart Lung Transplant, 2006, 25(12):1389-1395.
35
Khush KK, Patel J, Pinney S, et al. Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: a prospective multicenter study[J]. Am J Transplant, 201919(10):2889-2899.
36
Agbor-Enoh S, Shah P, Tunc I, et al. Cell-free DNA to detect heart allograft acute rejection[J]. Circulation, 2021143(12):1184-1197.
37
Holzhauser L, Clerkin KJ, Fujino T, et al. Donor-derived cell-free DNA is associated with cardiac allograft vasculopathy[J]. Clin Transplant, 202135(3):e14206
38
Afzal A, Alam A, van Zyl JS, et al. Observed elevated donor-derived cell free DNA in orthotopic heart transplant recipients without clinical evidence of rejection[J]. Clin Transplant, 202236(3):e14549.
39
Miller DV, Roden AC, Gamez JD, et al. Detection of C4d deposition in cardiac allografts: a comparative study of immunofluorescence and immunoperoxidase methods[J]. Arch Pathol Lab Med, 2010134(11):1679-1684.
40
Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis[J]. Science, 1995270(5234):286-290.
41
Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients[J]. J Heart Lung Transplant, 201029(8):914-956.
42
Leech SH, Lopez-Cepero M, LeFor WM, et al. Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin[J]. Clin Transplant, 200620(4):476-484.
43
Dall’Amico R, Montini G, Murer L, et al. Extracorporeal photochemotherapy after cardiac transplantation: a new therapeutic approach to allograft rejection[J]. Int J Artif Organs, 200023(1):49-54.
44
Kirklin JK, Brown RN, Huang ST, et al. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis[J]. J Heart Lung Transplant, 200625(3):283-288.
45
Barr ML, Baker CJ, Schenkel FA, et al. Prophylactic photopheresis and chronic rejection: effects on graft intimal hyperplasia in cardiac transplantation[J]. Clin Transplant, 200014(2):162-166.
46
Kyle RA, Rajkumar SV. Multiple myeloma[J]. N Engl J Med, 2004351(18):1860-1873. Erratum in: N Engl J Med, 2005,352(11):1163.
47
Garrett HE Jr, Duvall-Seaman D, Helsley B, et al. Treatment of vascular rejection with rituximab in cardiac transplantation[J]. J Heart Lung Transplant, 200524(9):1337-1342.
48
Keren A, Hayes HM, O’Driscoll G. Late humoral rejection in a cardiac transplant recipient treated with the anti-CD20 monoclonal antibody rituximab[J]. Transplant Proc, 200638(5):1520-1522.
49
Balfour IC, Fiore A, Graff RJ, et al. Use of rituximab to decrease panel-reactive antibodies[J]. J Heart Lung Transplant, 200524(5):628-630.
50
Woodside KJ, Lick SD. Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection[J]. J Heart Lung Transplant, 200726(7):750-752.
51
Wang H, Jiang J, Liu W, et al. Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine[J]. Transplantation, 200579(9):1121-1127.
52
Patel JK, Coutance G, Loupy A, et al. Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients[J]. Am J Transplant, 202121(7):2479-2488.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 易柏成, 李旭光, 王容容, 王新璇. 数字化3D打印导板应用于上前牙钙化根管治疗2例[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(06): 385-390.
[3] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[4] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[5] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[6] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[7] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[8] 石海波, 赵旭东, 王聪, 曲巍. 气肿性肾盂肾炎、气肿性膀胱炎并脓毒性休克一例报道并文献复习[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 644-647.
[9] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[10] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[11] 魏志鸿, 刘建勇, 吴小雅, 杨芳, 吕立志, 江艺, 蔡秋程. 肝移植术后急性移植物抗宿主病的诊治(附四例报告)[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 846-851.
[12] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[13] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[14] 张平骥, 徐钰, 李天水, 庞文翼, 符师宁, 张梦圆. 重症患者镇静治疗现状及期望的调查研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 562-567.
[15] 王昌前, 林婷婷, 宁雨露, 王颖杰, 谭文勇. 光免疫治疗在肿瘤领域的临床应用新进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 575-583.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?